Skip to main content

Outcomes

Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/YgtujQjNqI https://t.co/9uazZLuoRb
Dr. John Cush @RheumNow( View Tweet )
Conservative Treatment of Acute Vertebral Fractures A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term… https://t.co/uqQAoypdiV https://t.co/HNgKtzMs03
Dr. John Cush @RheumNow( View Tweet )

Different Autoantibody Phenotypes in Juvenile and Adult Myositis

A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.

Read Article
Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf
Dr. John Cush @RheumNow( View Tweet )
Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/kvtqXFUezw https://t.co/NrYi61yerm
Dr. John Cush @RheumNow( View Tweet )
JAMA: RCT in 101 chronic low back pain pts showed a single nondeceptive placebo injection reduced LBP intensity for 1 month https://t.co/RI9TnvmeMJ https://t.co/BF6UBqMXrD
Dr. John Cush @RheumNow( View Tweet )

Increasing Incidence of Morphea

A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.

Read Article
Wales registry of primary Unilateral knee replacements (UKRs) for #OA (n 106,206) found no outcome differences based on level of training (15 yr UKR failure rates equal for Trainees/16.4% vs Consultants/17.13% https://t.co/uIo4Sv8Lfu https://t.co/LEMrf3vHaR
Dr. John Cush @RheumNow( View Tweet )

ACR Speaks Against Repeated Cuts to Medicare Reimbursements

ACR

The American College of Rheumatology has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheumatologists and rheumatology interprofessional team members’ ability to provide care to the 53 million

Read Article

Low Placental Transfer Rates with Risankizumab

There are significant concerns about the safety of drug use during pregnancy and lactation, especially newer biologic agents. This is complicated by a lack of research. 

Read Article
Conservative Treatment of Acute Vertebral Fractures A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term… https://t.co/EulO6EGVxq https://t.co/H1yHPNMrQO
Dr. John Cush @RheumNow( View Tweet )
French retrospective study of 181 hemodialysis pts (97 on urate Rx-90% allopurinol, 9% febuxostat). W/ ULT pts had significantly fewer agout flare (HR:0.42; CI 95: 0.25-0.71). Overall flares 35% (23% ULT vs 50% w/o ULT; p 0.0002) https://t.co/9hTgsR2Kx9 https://t.co/Bef0T1po2c
Dr. John Cush @RheumNow( View Tweet )
Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi https://t.co/PtxRsTifi1
Dr. John Cush @RheumNow( View Tweet )

Consensus Guidelines on Pediatric Methotrexate Use

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Read Article

Moving Forward on RA Prevention Trials

Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.

Read Article

Conservative Treatment of Acute Vertebral Fractures

A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term benefits were superior for teriparatide compared to bisphosphonates.

Read Article
Sustained Hydroxychloroquine and Cardiovascular Outcomes A national cohort study shows that continuous use of hydroxychloroquine (HCQ) protects against cardiovascular (CV) events in patients with systemic lupus erythematosus (SLE). https://t.co/xqB2tyzzYQ https://t.co/dlFjbgbsep
Dr. John Cush @RheumNow( View Tweet )

Does Rheumatoid Factor Influence Anti-TNF Responses in RA?

Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated with adalimumab had a blunted response in the face of high RF titers.

Read Article
Metanalysis of Social determinants of health and lupus nephritis (31 studies) showed poor LN outcomes were 1.47-fold higher w/ any adverse SDoH. Also multiplicative impact of having two or more adverse SDoH on LN outcomes. https://t.co/4oEuAEgBx1 https://t.co/OkeRzrCXzQ
Dr. John Cush @RheumNow( View Tweet )

Immunomodulatory Prevention of Uveitis Relapse in Behçet's

The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease.

Read Article

Scleroderma Raynaud's May Worsen in Summer

MedPage Today

Episodes of Raynaud's phenomenon, a common feature of systemic sclerosis (SSc, also known as scleroderma), were more severe not only at low temperatures, as one would expect, but also during summertime heat, a multinational study found.

Read Article
Life Essential 8 (LE8) score studied in RA & SLE was neg. corrlated w/ DAS28 (r −0.96) & SLEDAI (r − 0.81) & assoc w/ 10 yr survival. LE8 score: smoking, sleep, physical activity, diet, BMI, non-HDL, BP, fasting glucose, & HgbA1c. https://t.co/DCpWKzmt80 https://t.co/eKqqEO1F65
Dr. John Cush @RheumNow( View Tweet )
Consumption of Alcohol and the Risk of Gout Alcohol is a risk factor for gout and flares. While the inciting potential differs among alcohol types, are these differences sex specific? https://t.co/CzE9ZSEN9f https://t.co/e4WBSBlNEo
Dr. John Cush @RheumNow( View Tweet )

Sustained Hydroxychloroquine and Cardiovascular Outcomes

A national cohort study shows that continuous use of hydroxychloroquine (HCQ) protects agains cardiovascular (CV) events in patients with systemic lupus erythematosus (SLE).

Read Article
Scleroderma skin findings in pts w/ skin of colour (SOC) - Raynauds was common but SOC pts had fewer hallmark Sxs: telangiectasias, calcinosis, digital swelling (complicating Dx). SOC had more severe pulmonary Dz & increased mortality, Atypical skin findings… https://t.co/8XkelxqvYE https://t.co/JOw8OSNjzw
Dr. John Cush @RheumNow( View Tweet )